Mass Spectrometry of Biopharmaceuticals – improved methodologies for qualitative, quantitative and structural characterisation of drugs, proteinaceous drug targets and diagnostic molecules. (Q84230)
Jump to navigation
Jump to search
Project Q84230 in Poland
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mass Spectrometry of Biopharmaceuticals – improved methodologies for qualitative, quantitative and structural characterisation of drugs, proteinaceous drug targets and diagnostic molecules. |
Project Q84230 in Poland |
Statements
3,499,706.0 zloty
0 references
3,499,706.0 zloty
0 references
100.0 percent
0 references
1 November 2017
0 references
31 October 2020
0 references
INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK
0 references
Mass Spectrometry (MS) expands into almost every area that requires qualitative and quantitative analysis of small molecules, including clinical applications. Its advantages include unsurpassed specificity, sensitivity better than most other analytical techniques, and ability to multiplex the analysis of many compounds in one analytical run. Since 2001 MS Lab IBB serves as a core MS laboratory for the community of biomedical sciences, implementing a variety of proteomic/metabolomic analyses for research groups from >70 institutions worldwide, both from academia and biopharma industry. It also provides immunosuppressive drug monitoring service for Polish transplant patients. We collaborate with numerous research groups from Poland and abroad, work out new data analysis tools and train students. Present project aims at improvements in analytical capabilities of the Lab and implementation of new procedures that will increase the scope of Lab activities or increase the results quality. (Polish)
0 references
Mass Spectrometry (MS) expands into almost every area that requires qualitative and quantitative analysis of small molecules, including clinical applications. It advantages include unsurpassed specificity, sensitivity better than most other analytical techniques, and ability to multiplex the analysis of many compounds in one analytical run. Since 2001 MS Lab IBB serves as a core MS laboratory for the community of biomedical sciences, implementing a variety of proteomic/metabolomic analyses for research groups from >70 institutions worldwide, both from academia and biopharma industry. It also provides immunosuppressive drug monitoring service for Polish transplant patients. We cooperate with numerous research groups from Poland and abroad, work out new data analysis tools and train students. Present project aims at improvements in analytical capabilities of the Lab and implementation of new procedures that will increase the scope of Lab activities or increase the results quality. (English)
14 October 2020
0 references
La spectrométrie de masse (SM) s’étend dans presque tous les domaines qui nécessitent une analyse qualitative et quantitative des petites molécules, y compris les applications cliniques. Ses avantages incluent la spécificité inégalée, la sensibilité meilleure que la plupart des autres techniques d’analyse, et la capacité de multiplexer l’analyse de nombreux composés en une seule série d’analyse. Depuis 2001, MS Lab IBB est un laboratoire de la SEP de base pour la communauté des sciences biomédicales, mettant en œuvre une variété d’analyses protéomiques/métaboliques pour des groupes de recherche de plus de 70 établissements du monde entier, issus à la fois du milieu universitaire et de l’industrie biopharmaceutique. Il fournit également un service de surveillance immunosuppressive des médicaments pour les patients transplantés polonais. Nous collaborons avec de nombreux groupes de recherche en Pologne et à l’étranger, nous élaborons de nouveaux outils d’analyse de données et nous formons des étudiants. Le présent projet vise à améliorer les capacités analytiques du laboratoire et à mettre en œuvre de nouvelles procédures qui élargiront la portée des activités du laboratoire ou amélioreront la qualité des résultats. (French)
30 November 2021
0 references
Identifiers
POIR.04.04.00-00-2CC8/16
0 references